胃癌患者外周血CD4+CD25+调节性T细胞的检测及其临床意义

目的探讨胃癌患者外周血CD4 CD25 调节性T细胞水平的特点及其临床意义。方法采用流式细胞术检测35例胃癌患者外周血CD4 CD25 调节性T细胞水平并进行分层分析。结果健康对照组CD4 CD25 调节性T细胞水平为(8.69±2.28)%,35例胃癌患者CD4 CD25 调节性T细胞比例为(17.77±8.45)%,统计学有显著差异(P<0.01);进一步分层分析显示随疾病进展外周血CD4 CD25 调节性T细胞水平升高,在III期、IV期尤为明显,统计学有极显著差异(P<0.01)。结论胃癌患者外周血CD4 CD25 调节性T细胞水平的升高与胃癌免疫功能低下及肿瘤的发生发展密切相关,去除这群细胞可有效诱导肿瘤免疫,为肿瘤治疗提供一种新的方法。     

CD4+CD25+调节性T细胞与大肠癌的关系

近来CD4 CD25 调节性T细胞对肿瘤免疫调节的抑制作用正受到越来越多的重视,许多恶性肿瘤患者外周血都存在CD4 CD25 调节性T细胞比例上调,机体抗肿瘤免疫力下降.大肠癌的发病率正逐年上升,其发病分子机制已为熟知,免疫机制研究不多,国内尚未见大肠癌与该类细胞关系的报道,现对CD4 CD25 调节性T细胞在大肠癌的发生、发展、治疗中的研究综述如下.     

肿瘤患者CD4+CD25+调节性T细胞流式细胞术分析

目的:分析比较肿瘤患者和健康人外周血CD4+CD25+调节性T细胞的特点,为肿瘤免疫学研究及治疗探索新方法.方法:收集并分离30例肿瘤患者和32例健康人的外周血单个核细胞(PBMCs),用荧光标记的抗人CD4及抗人CD25单抗标记肿瘤患者和健康人PBMCs细胞,FCM检测CD4+CD25+Treg细胞,分析CD4+CD25+Treg细胞在肿瘤患者和健康人中的差别.结果:肿瘤患者的CD4+CD25+Treg细胞百分数明显高于健康人(年龄<55者62.4 vs 40.4;年龄≥55者53.1 vs 31.0,P<0.05).结论:肿瘤患者的CD4+CD25+Treg细胞高于健康对照,为肿瘤免疫治疗提供新策略,通过删除CD4+CD25+Treg细胞,有可能增强抗瘤免疫反应.     

监测肾癌患者外周血CD4~+CD25~+调节性T细胞在术后免疫治疗中的作用

目的:探讨肾癌患者外周血CD4+CD25+T淋巴细胞的监测在术后辅助免疫治疗中的作用。方法:将24例肾癌患者随机分为两组:A组,根治性肾切除术后行IFN-α辅助免疫治疗;B组,单纯行根治性肾切除术;C组,10例健康对照。分别在术前、术后1周以及术后3个月免疫治疗结束时采集外周血样本,流式细胞仪检测CD4+、CD8+、CD4+CD25、CD4+CD25high T淋巴细胞亚群含量,并计算各部分比值。结果:A、B组术前CD4+CD25+、CD4+CD25high T淋巴细胞亚群总体上增加,并且其含量随肿瘤分期的进展而增加(P<0.05),但部分患者并不高于健康对照组。免疫治疗后,肾癌患者CD4+CD25+T淋巴细胞总体略有上升,但术前较高的患者中,约2/3下降。结论:利用流式细胞仪监测肾癌患者外周血CD4+CD25+T淋巴细胞亚群可反映机体抗肿瘤免疫状态,有助于预测免疫治疗的预后,为肾癌尤其是早期肾癌术后辅助免疫治疗的选择提供参考。     

结直肠癌患者外周血CD4+ CD25high调节性T细胞的作用

目的探讨结直肠癌患者外周血CD4+CD25high调节性T细胞(Treg)的作用。方法采用流式细胞仪测定36例结直肠癌患者及30例健康对照者外周血中CD4+CD25highFoxP3 Treg、CD4+CD25highTreg、CD4+CTLA-4 Treg及CD4+T细胞水平。结果与健康对照组比较,结直肠癌组患者外周血CD4+CD25highFoxP3 Treg显著增多(P<0.01),CD4+CD25high Treg和CD4+CTLA-4 T细胞也增多(P<0.05)。结论CD4+CD25highFoxP3 Treg可能在结直肠癌发展过程中起着重要作用。     

鼻咽癌组织与外周血CD4+CD25+调节性T细胞检测及临床意义

目的 通过检测鼻咽癌患者肿瘤组织及外周血中CD4+T、CD8+T、CD4+CD25T、CD4+CD25+T细胞的频数,寻找客观、全面评价鼻咽癌患者免疫状态的临床指标.方法 采用流式细胞术检测40例初诊鼻咽癌患者及10例正常时照鼻咽部组织和外周血CD4+T、CD8+T、CD4+CD25-T、CD4+CD25+T细胞比例.结果 鼻咽癌患者CD4+T细胞比例及CD4+/CD8+T比值均低于对照组(P<0.05),而CD8+T细胞两组间差异无统计学意义(P>0.05),但是CD4+/CD8+T比值在鼻咽癌组织与外周血间差异无统计学意义(P>0.05).鼻咽癌组织及外周血中CD4+CD25+T细胞比例都高于对照组(P<0.05),同时癌组织中该细胞比例远远高于外周血(P<0.05).在鼻咽癌组织中CD4+CD25+T细胞与CD8+T细胞、CD4+CDQ5-T细胞呈负相关(r分别为-0.70、-0.675,P<0.05),而在外周血中没有相关关系(P>0.05).在不同T(原发肿瘤大小)组间,T4组的鼻咽癌组织中CD4+CD25+T细胞分别高于T1、T2、T3各组(P<0.05).而在T1、T2、T3各组间差异无统计学意义(P>0.05);鼻咽癌中CD4+CD25+T细胞比例与患者有无淋巴结转移并无关系(P>0.05);鼻咽癌组织中Ⅲ+Ⅳ期组CD4+CD25+T细胞比例高于Ⅰ+Ⅱ期组(P<0.05),而在外周血中两组间差异无统计学意义(P>0.05).结论 CD4+CD25+T细胞与鼻咽癌病程进展无相关性,但是联合检测患者肿瘤组织及外周血中CD4+CD25+T细胞的频数并结合既往CD4+/CD8+T比值会全面反应患者免疫状态,为临床治疗提供依据.     

CD+4 CD+25 调节性T细胞与急性髓细胞白血病关系的研究

 目的　探讨CD+4 CD+25 调节性T细胞（CD+4 CD+25 Treg细胞）在急性髓细胞白血病（AML）患者化疗前后外周血中的表达水平及其临床意义。方法　采用流式细胞术检测AML初发组（A组）、缓解3年内组（B组）、缓解3年以上组（C组）及正常对照组外周血中CD+4 CD+25 CDlow127 T细胞所占比例。结果　A组和B组外周血中CD+4 CD+25 Treg细胞比例均高于对照组（P＜0.05）;C组外周血CD+4 CD+25 Treg细胞比例与对照组相比差异无统计学意义（P＞0.05）;B组外周血中CD+4 CD+25 Treg细胞比例高于C组（P＜0.05）;A组外周血中CD+4 CD+25 Treg细胞比例明显高于B、C两组（P＜0.05）。结论　CD+4 CD+25 Treg细胞与AML发生有关,尤其与3年内容易复发密切相关。     

胃癌患者外周血中CD4~+CD25~(high)FOXP3~+调节性T细胞的检测及临床意义

目的探讨胃癌患者外周血CD4+CD25highFOXP3+调节性T细胞(Treg)的检测及临床意义。方法选取60例胃癌患者(胃癌组)和60例健康体检者(健康对照组),采用流式细胞仪检测外周血中CD4+CD25highFOXP3+Treg细胞、CD4+CD25highT细胞及CD4+T细胞水平,酶联免疫吸附法检测外周血白介素10(IL-10)和转化生长因子β1(TGF-β1)浓度。结果与健康对照组相比,胃癌组患者外周血中CD4+CD25highFOXP3+Treg细胞和CD4+CD25highT细胞比例增高;IL-10和TGF-β1浓度增高,差异均有统计学意义(均P<0.05)。结论 CD4+CD25highFOXP3+Treg细胞可能与胃癌发生发展密切相关,为胃癌免疫治疗提供新思路。     

乳腺癌患者外周血CD4+CD25+调节性T细胞的检测及意义

目的探讨乳腺癌患者外周血中CD4+CD25+调节性T细胞的变化及意义.方法采用流式细胞技术检测64例乳腺癌患者外周血中CD4+CD25+调节性T细胞,采用ELISA法检测外周血中转化生长因子-β1(TGF-β1)的表达水平.结果乳腺癌患者外周血中CD4+CD25+调节性T细胞占T淋巴细胞的百分比为(5.1±2.9)%,高于乳腺良性肿物患者和健康志愿者(P均<0.05).乳腺癌患者外周血中CD4+CD25+T细胞水平与肿物大小、TGF-β1呈正相关(r分别为0.511和0.253),与CD8+CD28+T细胞和NK细胞呈负相关(r分别为-0.243和-0.301).结论乳腺癌患者外周血中具有免疫抑制活性的CD4+CD25+调节性T细胞水平较高,对乳腺癌患者具有免疫抑制作用.     

原发性肝癌患者CD4+CD25+CD127low调节性T细胞的检测及意义

探讨CD4+CD25+CD127low调节性T细胞（Tregs）在原发性肝细胞性肝癌（HCC）患者外周血中的变化及其临床意义。方法：采集40例乙型肝炎病毒（HBV）相关的HCC患者［巴塞罗那临床肝癌（BCLC）分期A期患者7例、B期患者8例、C期患者20例、D期患者5例］、35例慢性乙型肝炎（CHB）患者及28例正常健康人的外周抗凝血,应用CD4（PE-CY5）、CD25（FITC）、CD127（PE）三种特异性荧光抗体标记后,通过流式细胞术对CD4+CD25+CD127lowTregs水平进行三色荧光抗体检测。结果：HCC患者外周血CD4+CD25+CD127lowTregs占CD4+T细胞的百分比显著高于正常健康人（P<0.001）和CHB患者（P=0.017）,CHB患者外周血CD4+CD25+CD127lowTregs占CD4+T细胞的百分比高于正常健康人（P=0.035）;HCC中BCLC分期为C期的患者外周血CD4+CD25+CD127lowTregs占CD4+T细胞的百分比显著高于A期患者（P=0.020）和B期患者（P=0.019）。结论：CD4+CD25+CD127lowTregs水平异常增高可能是HCC免疫逃逸的一个重要机制,且其变化水平与临床病情的进展存在一定的相关性。     

贲门癌患者外周血CD4+CD25hiCD127low调节性T细胞水平及其临床意义

Objective To analyse the dysfunction of immunity and clinical significance in patients with cardiac cancer.Methods The level of CD4+ CD25hi CD127low Treg cells were detected by flow cytometry (FCM),and serum IL-10 and TGF-β1 levels were determined by enzyme linked immunosorbent assay (ELISA) kit in 56 patients with cardiac cancer.15 healthy volunteers were tested as normal controls.The clinical data of each patient were collected and analyzed. Results There was a significantly higher percentage of CD4+ CD25hi CD127low Treg cells in patients with cardiac cancer (5.73±1.56)% than that (4.45±1.06)% of healthy volunteers (P<0.01).The IL-10 and TGF-β1 levels in the serum of patients with cardiac cancer were also significantly higher than that of healthy volunteers (P<0.05).There was a positive correlation between levels of IL-10.TGF-β1 and the levels of CD4+ CD25hi CD127low Treg cells.The number of CD4+ CD25hi CD127low regulatory T cells in the peripheral blood of cardiac cancer patients were significantly correlated with clinical stages and metastasis lymph node.Conclusion The CD4+ CD25hi CD127low Treg cells in the peripheral blood of cardiac cancer patients is significantly increased in comparison with that in healthy volunteers,and was also correlated with different stages.The abnormal levels of CD4+ CD25hi CD127low Treg cells may be related to tumor progression in patients with cardiac cancer.     

贲门癌患者外周血CD4+CD25hiCD127low调节性T细胞水平及其临床意义

Objective To analyse the dysfunction of immunity and clinical significance in patients with cardiac cancer.Methods The level of CD4+ CD25hi CD127low Treg cells were detected by flow cytometry (FCM),and serum IL-10 and TGF-β1 levels were determined by enzyme linked immunosorbent assay (ELISA) kit in 56 patients with cardiac cancer.15 healthy volunteers were tested as normal controls.The clinical data of each patient were collected and analyzed. Results There was a significantly higher percentage of CD4+ CD25hi CD127low Treg cells in patients with cardiac cancer (5.73±1.56)% than that (4.45±1.06)% of healthy volunteers (P<0.01).The IL-10 and TGF-β1 levels in the serum of patients with cardiac cancer were also significantly higher than that of healthy volunteers (P<0.05).There was a positive correlation between levels of IL-10.TGF-β1 and the levels of CD4+ CD25hi CD127low Treg cells.The number of CD4+ CD25hi CD127low regulatory T cells in the peripheral blood of cardiac cancer patients were significantly correlated with clinical stages and metastasis lymph node.Conclusion The CD4+ CD25hi CD127low Treg cells in the peripheral blood of cardiac cancer patients is significantly increased in comparison with that in healthy volunteers,and was also correlated with different stages.The abnormal levels of CD4+ CD25hi CD127low Treg cells may be related to tumor progression in patients with cardiac cancer.     

贲门癌患者外周血CD4+CD25hiCD127low调节性T细胞水平及其临床意义

目的 探讨贲门癌患者的免疫功能异常及其临床意义.方法 采用流式细胞术(FCM)和酶联免疫吸附(ELISA)方法分别检测56例贲门癌患者、15名健康人外周血中CD4+CD25hiCD127lowc调节性T细胞(Treg细胞)和血清IL-10、TGF-β1水平,结合临床资料进行分析.结果 56例贲门癌患者外周血中CD4+CD25hiCD127lowTreg细胞占CD4+淋巴细胞的比例为(5.73±1.56)%,与健康对照组的(4.45±1.06)%相比,差异有统计学意义(P<0.01);血清中IL-10和TGF-β1含量均明显高于健康对照(P<0.05).贲门癌患者外周血CD4+CD25hiCD127low Treg细胞水平与血清IL-10和TGF-β1含量呈正相关.贲门癌患者外周血CD4+CD25hiCD127low Treg细胞数量与患者临床分期、淋巴结转移有关.结论 贲门癌患者外周血中CD4+CD25hiCD127low Treg细胞表达增高,与临床分期有关,提示Treg水平异常与贲门癌的发生发展密切相关.     

恶性肿瘤患者外周血CD4+CD25+调节T细胞的检测及其临床意义

目的探讨恶性肿瘤外周血CD4+CD25+调节T细胞水平的特点及其临床意义.方法采用流式细胞术检测53例恶性肿瘤患者外周血CD4+CD25+调节T细胞水平及淋巴细胞亚群,并进行分层分析.结果外周血淋巴细胞亚群分析显示恶性肿瘤患者CD4、CD16阳性细胞比例在早期(Ⅰ+Ⅱ期)患者即低于对照组,但差异无显著性意义(P＞0.05),CD4/CD8亦低于对照组,差异有显著性意义(P＜0.05);随着疾病进展(Ⅲ、Ⅳ期)CD4、CD4/CD8、CD16阳性细胞比例减低明显,差异有显著性意义(P＜0.05);各期CD8、CD19、CD3与对照组接近(P＞0.05).外周血CD4+CD25+调节T细胞比例健康对照组CD4+CD25+T细胞水平为(14.49±4.69)%,恶性肿瘤53例CD4+CD25+T细胞比例为(19.61±8.17)%,统计学有差异(P＜0.05);进一步分层分析显示随疾病进展外周血CD4+CD25+T细胞水平升高,在肿瘤进展期(Ⅳ期)尤其明显,统计学有极显著差异(P＜0.01).结论恶性肿瘤患者外周血CD4+CD25+调节T细胞水平的升高,与恶性肿瘤免疫功能低下及肿瘤的发生发展密切相关.去除这群细胞可有效诱导肿瘤免疫,为肿瘤治疗提供一种新的方法.     

肺癌患者外周血CD+4CDHi25CDLo127调节性T细胞检测的临床意义

Objective To evaluate the changes and clinical significance of CD+4CDHi25CDLo127 regulatory T cell(Treg) in peripheral blood of patients with lung cancer. Methods 30 patients with lung cancer and 20 heathy volunteers were included in this study. The proportion of Treg population in CD4+ T cells stained with three colors was analysed by flow cytometry. The serum level of IL-10 and TGF-β were measured by ELISA. Results The proportion of Treg in patients with squamous cell careinoma(n=20), adenocarcinoma (n=10) were all significantly higher than that of healthy controls (P <0.05), but there was not obvious difference between the two groups with different pathological types(P0.05). Increased serum level of IL-10 and TGF-β was also detected in lung cancer patients. Conclusion The proportion of Treg is increased in lung cancer patients, which may result in the inhibition of host anti-cancer immune response by excreting IL-10 and TGF-β.     

肺癌患者外周血CD+4CDHi25CDLo127调节性T细胞检测的临床意义

Objective To evaluate the changes and clinical significance of CD+4CDHi25CDLo127 regulatory T cell(Treg) in peripheral blood of patients with lung cancer. Methods 30 patients with lung cancer and 20 heathy volunteers were included in this study. The proportion of Treg population in CD4+ T cells stained with three colors was analysed by flow cytometry. The serum level of IL-10 and TGF-β were measured by ELISA. Results The proportion of Treg in patients with squamous cell careinoma(n=20), adenocarcinoma (n=10) were all significantly higher than that of healthy controls (P <0.05), but there was not obvious difference between the two groups with different pathological types(P0.05). Increased serum level of IL-10 and TGF-β was also detected in lung cancer patients. Conclusion The proportion of Treg is increased in lung cancer patients, which may result in the inhibition of host anti-cancer immune response by excreting IL-10 and TGF-β.     

肺癌患者外周血CD+4CDHi25CDLo127调节性T细胞检测的临床意义

Objective To evaluate the changes and clinical significance of CD+4CDHi25CDLo127 regulatory T cell(Treg) in peripheral blood of patients with lung cancer. Methods 30 patients with lung cancer and 20 heathy volunteers were included in this study. The proportion of Treg population in CD4+ T cells stained with three colors was analysed by flow cytometry. The serum level of IL-10 and TGF-β were measured by ELISA. Results The proportion of Treg in patients with squamous cell careinoma(n=20), adenocarcinoma (n=10) were all significantly higher than that of healthy controls (P <0.05), but there was not obvious difference between the two groups with different pathological types(P0.05). Increased serum level of IL-10 and TGF-β was also detected in lung cancer patients. Conclusion The proportion of Treg is increased in lung cancer patients, which may result in the inhibition of host anti-cancer immune response by excreting IL-10 and TGF-β.     

肺癌患者外周血CD+4CDHi25CDLo127调节性T细胞检测的临床意义

Objective To evaluate the changes and clinical significance of CD+4CDHi25CDLo127 regulatory T cell(Treg) in peripheral blood of patients with lung cancer. Methods 30 patients with lung cancer and 20 heathy volunteers were included in this study. The proportion of Treg population in CD4+ T cells stained with three colors was analysed by flow cytometry. The serum level of IL-10 and TGF-β were measured by ELISA. Results The proportion of Treg in patients with squamous cell careinoma(n=20), adenocarcinoma (n=10) were all significantly higher than that of healthy controls (P <0.05), but there was not obvious difference between the two groups with different pathological types(P0.05). Increased serum level of IL-10 and TGF-β was also detected in lung cancer patients. Conclusion The proportion of Treg is increased in lung cancer patients, which may result in the inhibition of host anti-cancer immune response by excreting IL-10 and TGF-β.     

肺癌患者外周血CD+4CDHi25CDLo127调节性T细胞检测的临床意义

Objective To evaluate the changes and clinical significance of CD+4CDHi25CDLo127 regulatory T cell(Treg) in peripheral blood of patients with lung cancer. Methods 30 patients with lung cancer and 20 heathy volunteers were included in this study. The proportion of Treg population in CD4+ T cells stained with three colors was analysed by flow cytometry. The serum level of IL-10 and TGF-β were measured by ELISA. Results The proportion of Treg in patients with squamous cell careinoma(n=20), adenocarcinoma (n=10) were all significantly higher than that of healthy controls (P <0.05), but there was not obvious difference between the two groups with different pathological types(P0.05). Increased serum level of IL-10 and TGF-β was also detected in lung cancer patients. Conclusion The proportion of Treg is increased in lung cancer patients, which may result in the inhibition of host anti-cancer immune response by excreting IL-10 and TGF-β.